BioCentury | Dec 21, 2018
Financial News

Proteomics company Seer launches with $36M

...Proteomics Inc. (San Diego, Calif.) and Affymetrix Inc. vet John Blume as VP of research; Crescendo Bioscience Inc....
BioCentury | Dec 17, 2018
Company News

Proteomics company Seer launches with $36M

...Proteomics Inc. (San Diego, Calif.) and Affymetrix Inc. vet John Blume as VP of research; Crescendo Bioscience Inc....
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Sep 4, 2015
Company News

Management tracks

Musculoskeletal company Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) hired Ralf Rosskamp as CMO. Rosskamp was VP of global clinical development at NPS Pharmaceuticals Inc. , which Shire plc (LSE:SHP; NASDAQ;SHPG) acquired. The Crescendo Biosciences unit of Myriad...
BioCentury | Jan 5, 2015
Company News

Myriad Genetics management update

...Inc. (NASDAQ:MYGN), Salt Lake City, Utah Business: Diagnostic Hired: Bernard Tobin as president of Myriad’s Crescendo Bioscience Inc....
BioCentury | Feb 10, 2014
Company News

Crescendo Bioscience, Myriad Genetics deal

...to contribute about $10 million in revenue for the fiscal year ending June 30, 2014. Crescendo Bioscience Inc....
BioCentury | Feb 10, 2014
Finance

Highlights of weekly biotech stock moves

...second quarter of its fiscal year ending June 30, 2014, and announced it will acquire Crescendo Bioscience Inc....
BioCentury | Feb 10, 2014
Analyst Picks & Changes

Analyst picks & changes

...his $29.65 target after Myriad reported earnings and said it will acquire molecular diagnostics company Crescendo Bioscience Inc....
BioCentury | Feb 5, 2014
Company News

Myriad to acquire Crescendo

...second quarter for its fiscal year ending June 30, 2014, and announced it will acquire Crescendo Bioscience Inc....
BioCentury | Jan 6, 2014
Finance

Replacing what Myri-had

...and commercial infrastructure. For example, he suggested Myriad could exercise its 2011 option to acquire Crescendo Bioscience Inc....
Items per page:
1 - 10 of 27
BioCentury | Dec 21, 2018
Financial News

Proteomics company Seer launches with $36M

...Proteomics Inc. (San Diego, Calif.) and Affymetrix Inc. vet John Blume as VP of research; Crescendo Bioscience Inc....
BioCentury | Dec 17, 2018
Company News

Proteomics company Seer launches with $36M

...Proteomics Inc. (San Diego, Calif.) and Affymetrix Inc. vet John Blume as VP of research; Crescendo Bioscience Inc....
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Sep 4, 2015
Company News

Management tracks

Musculoskeletal company Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) hired Ralf Rosskamp as CMO. Rosskamp was VP of global clinical development at NPS Pharmaceuticals Inc. , which Shire plc (LSE:SHP; NASDAQ;SHPG) acquired. The Crescendo Biosciences unit of Myriad...
BioCentury | Jan 5, 2015
Company News

Myriad Genetics management update

...Inc. (NASDAQ:MYGN), Salt Lake City, Utah Business: Diagnostic Hired: Bernard Tobin as president of Myriad’s Crescendo Bioscience Inc....
BioCentury | Feb 10, 2014
Company News

Crescendo Bioscience, Myriad Genetics deal

...to contribute about $10 million in revenue for the fiscal year ending June 30, 2014. Crescendo Bioscience Inc....
BioCentury | Feb 10, 2014
Finance

Highlights of weekly biotech stock moves

...second quarter of its fiscal year ending June 30, 2014, and announced it will acquire Crescendo Bioscience Inc....
BioCentury | Feb 10, 2014
Analyst Picks & Changes

Analyst picks & changes

...his $29.65 target after Myriad reported earnings and said it will acquire molecular diagnostics company Crescendo Bioscience Inc....
BioCentury | Feb 5, 2014
Company News

Myriad to acquire Crescendo

...second quarter for its fiscal year ending June 30, 2014, and announced it will acquire Crescendo Bioscience Inc....
BioCentury | Jan 6, 2014
Finance

Replacing what Myri-had

...and commercial infrastructure. For example, he suggested Myriad could exercise its 2011 option to acquire Crescendo Bioscience Inc....
Items per page:
1 - 10 of 27